NK1 antagonists
- Block substance-P NK1 signaling
- Major role: chemotherapy nausea prevention
- Aprepitant/fosaprepitant/netupitant/rolapitant
- Best for delayed emesis in combinations
- CYP3A interactions vary substantially
- Aprepitant changes dexamethasone exposure
- Not generally stand-alone rescue drugs
Class at a glance
- Block substance-P NK1 signaling
Pharmacology
- CYP3A interactions vary substantially
Clinical role
- Major role: chemotherapy nausea prevention
- Aprepitant/fosaprepitant/netupitant/rolapitant
Members / distinctions
- Best for delayed emesis in combinations
- Aprepitant changes dexamethasone exposure
- Not generally stand-alone rescue drugs
Self-check
- What is the major clinical role of NK1 antagonists?
Chemotherapy nausea prevention. - When are NK1 antagonists especially useful?
Delayed emesis in combination regimens.
Drugs in this class (3)
NK1 antagonists prescription history
Animated chart of estimated U.S. prescriptions per year, Antiemetics (1946–2026). NK1 antagonists highlighted from 2003.
All drug classes · Open NK1 antagonists in the interactive console ↗